Sherry Li
Pfizer
16 Papers
89 Citations
Sherry Li is an academic researcher from Pfizer. The author has contributed to research in topics: Crizotinib & Sunitinib. The author has an hindex of 10, co-authored 16 publications.
Chat about Author
Papers
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T. Shaw,Benjamin Solomon,Benjamin Besse,Todd M. Bauer,Chia-Chi Lin,Ross A. Soo,Gregory J. Riely,Sai-Hong Ignatius Ou,Jill S. Clancy,Sherry Li,Antonello Abbattista,Holger Thurm,Miyako Satouchi,D. Ross Camidge,Steven Kao,Rita Chiari,Shirish M. Gadgeel,Enriqueta Felip,Jean-Francois Martini +18 more
TL;DR: Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.
344
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon,Alexander Drilon,Jeffrey W. Clark,Jared Weiss,Sai-Hong Ignatius Ou,D. Ross Camidge,Benjamin Solomon,Gregory A. Otterson,Liza C. Villaruz,Gregory J. Riely,Rebecca S. Heist,Mark M. Awad,Geoffrey I. Shapiro,Miyako Satouchi,Toyoaki Hida,Hidetoshi Hayashi,Danielle Murphy,Sherry C. Wang,Sherry Li,Tiziana Usari,Keith D. Wilner,Paul K. Paik +21 more
TL;DR: An unmet need for targeted therapy in people with lung cancers with MET exon 14 alterations is addressed and crizotinib is added to an expanding list of genomically driven therapies for oncogenic subsets of NSCLC.
329
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T. Shaw,Benjamin Solomon,Rita Chiari,Gregory J. Riely,Benjamin Besse,Benjamin Besse,Ross A. Soo,Steven Kao,Chia-Chi Lin,Todd M. Bauer,Jill S. Clancy,Holger Thurm,Jean-Francois Martini,Gerson Peltz,Antonello Abbattista,Sherry Li,Sai-Hong Ignatius Ou +16 more
TL;DR: Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with CNS metastases and those previously treated with crizotinib, and could represent an important next-line targeted agent.
303
A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner,Wells A. Messersmith,Naveed Shaik,Sherry Li,Xianxian Zheng,Karen McLachlan,Rossano Cesari,Rachel Courtney,Wendy J. Levin,Anthony B. El-Khoueiry +9 more
TL;DR: The results obtained in this study support further evaluation of PF-04449913 in patients with advanced solid tumors and indicate a generally dose-proportional kinetics with biphasic elimination, supporting once-daily dosing.
66
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
A. Drilon,Jeffrey W. Clark,Jared Weiss,S-H.I. Ou,D.R. Camidge,Ben Solomon,Greg Otterson,Liza C. Villaruz,G. J. Riely,Rebecca S. Heist,Geoffrey I. Shapiro,Danielle Murphy,Sherry C. Wang,Tiziana Usari,Sherry Li,Keith D. Wilner,Paul K. Paik +16 more
TL;DR: This data indicates that the once-weekly treatment with Crizotinib in patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer is a viable treatment option for these patients with atypical EGFRs.
33